Gene Therapy Fulfilling Its Promise
Donald B. Kohn, M.D., and Fabio Candotti, M.D.

From its earliest conception, gene therapy held the promise of correcting inherited diseases by inserting a normal copy of the relevant gene into somatic cells.1 Common monogenic diseases of blood cells, such as sickle cell disease or β-thalassemia, were originally considered important candidates for gene therapy because they were well understood at the molecular level and because the target cell, the hematopoietic stem cell, is easily accessible and can be explanted, genetically corrected in the laboratory, and then retransplanted.2 The advantage of gene therapy over the conventional transplantation of hematopoietic stem cells from compatible donors is that gene therapy is in principle available to all patients and should avert the problems of the immunologic barriers that can lead to graft rejection or graft-versus-host disease. It was soon recognized, however, that the technical challenges of correcting hemoglobin disorders by means of gene therapy were daunting, most likely requiring gene transfer in high numbers of hematopoietic stem cells and high levels of expression of the β-globin gene in erythrocyte precursors.

Thus, in the mid-1980s, several groups turned to a far rarer disorder, severe combined immunodeficiency disease (SCID) due to deficiency of the enzyme adenosine deaminase (ADA), which was considered to be potentially more tractable with the gene-transfer techniques that were then available. It was known from experience with patients who had SCID and an HLA-matched sibling who could be a hematopoietic stem-cell donor that there is a strong selective-amplification effect whereby only a small amount of engrafted marrow can completely restore the immune system.3 Thus, if the ADA gene could be inserted even into only a modest number of hematopoietic stem cells obtained from a patient with SCID due to ADA deficiency and be expressed in the progeny blood cells produced after retransplantation of the transduced cells, there is a good chance of clinical benefit.

Initial efforts at gene therapy for SCID due to ADA deficiency in the early 1990s did not produce the cures that had been hoped for, probably because of the low numbers of gene-corrected hematopoietic stem cells that were engrafted in the first handful of patients.4,5 These pioneer experiments were followed by incremental improvements in the laboratory techniques used to introduce genes into hematopoietic stem cells, and a second generation of clinical trials were begun in the late 1990s, directed at both SCID due to ADA deficiency and the X-linked form of SCID.

Thus, in 2000 and 2002, investigators from France and Italy reported results suggesting that the fulfillment of the promise of gene therapy was at hand. Cavazzana-Calvo et al.6 reported immune reconstitution in five infants with X-linked SCID who underwent gene therapy in Paris, and Aiuti et al.7 described initial signs of immune reconstitution in two infants with SCID due to ADA deficiency treated in Milan. The gene-transfer methods used in the two studies were similar, but only the patients with SCID due to ADA deficiency were given a chemotherapeutic agent, busulfan, intended to “make space” for the gene-corrected hematopoietic stem cells to enhance their engraftment after infusion. Except for the expected transient neutropenia and thrombocytopenia, the clinical effects of the reduced dose of busulfan chemotherapy used in the study were much milder than those of the “full-dose” conditioning typically used for bone marrow transplantation. Since these two studies were published, the encourag-
The results by Aiuti et al. present a key difference from those of the two gene-therapy trials of X-linked SCID. Although 18 of 20 treated infants with X-linked SCID are alive and well with restored immunity, a T-cell lymphoproliferative syndrome developed within 2 to 5 years after the procedure in 5 children; 1 of these children died as a consequence of complications of the syndrome, despite therapy. Investigations have implicated insertional oncogenesis in the pathogenesis of the leukemia-like illness, in which the insertion of the corrective retroviral vector may activate expression of cellular proto-oncogenes near the integration site. \(^8\)

The sharp dichotomy between the absence of this complication in the patients with SCID due to ADA deficiency and its occurrence in 25% of the patients with X-linked SCID is important to understand if we are to retain the therapeutic efficacy of gene therapy while minimizing its risks. The time to immune recovery in the patients with SCID due to ADA deficiency is markedly slower (6 to 12 months) than the rapid development (over 3 to 6 months) of T cells in the patients with X-linked SCID receiving gene therapy, which may reflect important biologic differences between the corrected hematopoietic stem cells in X-linked SCID and SCID due to ADA deficiency.

The gene responsible for X-linked SCID encodes the common γ (γc) chain, a component of the receptor for multiple cytokines involved in lymphocyte development and function. The γc protein provides a proliferation signal that may cooperate with the concomitantly deregulated expression of a proto-oncogene in proximity to the gene-transfer vector-integration site, favoring the establishment of malignant cells. On the contrary, ADA expression merely provides protection against apoptosis in ADA-deficient cells, which is expected to place less selective pressure on the survival of ADA-deficient hematopoietic stem cells containing vector integrations that might have caused oncogene activation.

Despite the widely publicized adverse events in the X-linked SCID trials, it is vital to dispassionately compare gene-therapy results with those of the current standard of care. Transplantation of parental or unrelated allogeneic hematopoietic stem cells in the approximately 80% of infants with SCID who lack an HLA-matched sibling donor has success rates of 50 to 85%, with a considerable number of patients dying from a host of complications. Certainly, the outcomes of gene therapy for SCID reported in recent trials are at least as good as, and arguably better than, the results reported for allogeneic transplantation, justifying further study of this procedure that, in the case of SCID due to ADA deficiency, has already received orphan-drug status by the European Medicines Agency.

The prospects for continuing advancement of gene therapy to wider applications remain strong. Ongoing and upcoming clinical trials will use safer designs of retroviral vectors, newer types of vectors for viral gene delivery, and emerging methods for direct in situ gene repair (Fig. 1). These
Self-inactivating vectors to eliminate strong LTR enhancers

Cellular promoters for more physiologic regulation of gene expression

5′ LTR Promoter Therapeutic gene 3′ LTR

Retroviral vector

Chromatin insulators and other boundary elements to block transactivation

Viral vectors with better gene-transfer and integration-site choices

Integration

Promoter Therapeutic gene

Murine γ-retroviruses

Lentiviruses, foamy viruses, and nonmurine retroviruses

Cellular gene

Hematopoietic stem cell

Direct in situ gene repair to obviate random gene insertion

Homologous recombination

Non–chemotherapy-based methods to “make space”

Monoclonal antibodies

Copyright © 2009 Massachusetts Medical Society. All rights reserved.
Figure 1 (facing page). Increasing the Safety and Efficacy of Gene Therapy through the Use of Hematopoietic Stem Cells.

Long-lasting gene correction of hematopoietic stem cells requires persistence of the corrective gene for it to be passed on to all the progeny blood cells. At least six methods that ensure such persistence in ways that are safer for patients, yet still retain the efficacy seen in the clinical trials of gene therapy for severe combined immunodeficiency disease (SCID), are under study. The first method is the use of self-inactivating vectors to eliminate strong long terminal repeat (LTR) enhancers. The LTR sequences at the ends of retroviral-vector sequences possess strong enhancer activity that may play a key role in the transactivation of adjacent cellular proto-oncogenes. Vector designs that lead to “self-inactivation” of these LTR enhancer sequences have significantly reduced transactivation activity. The second method is the use of cellular promoters for increased physiologic regulation of gene expression. The use of the promoters of cellular genes, rather than the strong viral promoters often used in vectors, to drive expression of the therapeutic gene may reduce the risks of activating adjacent cellular genes. The third method is the use of chromatin insulators and other genomic boundary elements to block transactivation. DNA sequences present throughout the genome act to block interactions between adjacent transcriptional units, and these boundary elements (including insulators and matrix-attachment regions) may prevent integrated vectors from transactivating adjacent cellular genes. The fourth method is the use of gene-transfer vectors that make better gene-transfer and integration-site choices. The gene-transfer vectors used in most studies to date, derived from murine γ-retroviruses, have a high predisposition toward integrating near the 5′ ends of cellular genes, close to the transcriptional control elements of the cellular gene. Newer vectors being developed from lentiviruses, foamy viruses, and nonmurine retroviruses (such as avian sarcoma and leukemia virus) tend to integrate across broader regions of the genome, which may decrease their potential to transactivate cellular genes. The fifth method is the use of direct in situ gene repair to obviate random gene insertion. Methods to perform gene repair by means of efficient homologous recombination are being developed, aided by sequence-specific endonucleases that facilitate the process. Gene correction, rather than gene addition, would not lead to random insertion of transgene sequences. The sixth method is the use of non–chemotherapy-based approaches to favor safer engraftment of gene-corrected stem cells. In the study by Aiuti et al., a chemotherapeutic agent, busulfan, was administered to patients to “make space” in their bone marrow for the gene-treated stem cells to engraft. Methods that use less-toxic agents, such as monoclonal antibodies that bind to and deplete stem cells, may be able to facilitate stem-cell engraftment with fewer potential short- and long-term side effects.

approaches to the treatment of hemoglobinopathies, hemophilia, muscular dystrophy, congenital retinopathies, neurodegenerative disorders, and other genetic diseases may further fulfill the promise that gene therapy made two decades ago.

No potential conflict of interest relevant to this article was reported.

From the Division of Research Immunology–Bone Marrow Transplantation, Childrens Hospital Los Angeles, and the Department of Pediatrics, Keck School of Medicine of the University of Southern California — both in Los Angeles (D.B.K.); and the Department of Immunology–Bone Marrow Transplantation, Childrens Hospital Los Angeles, and the Division of Research Immunology–Bone Marrow Transplantation, Childrens Hospital Los Angeles, and the Department of Pediatrics, Keck School of Medicine of the University of Southern California — both in Los Angeles (D.B.K.); and the Disorders of Immunity Section, Genetics and Molecular Biology Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD (F.C.).


Copyright © 2009 Massachusetts Medical Society.